Evidence map›Paper›PMID 21864343›Full record

Trial reportMalaria journal2011

A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.

Seif A Shekalaghe, Chris Drakeley, Sven van den Bosch, Roel ter Braak, Wouter van den Bijllaardt, Charles Mwanziva, Salimu Semvua, Alutu Masokoto, Frank Mosha, Karina Teelen and 5 more

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Malaria journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 9 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00509015 nacompletednot on this map

Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine

TypeinterventionalSponsorRadboud University Medical CenterRan2008 to 2008Enrolled6,000ConditionsMalaria, FalciparumArmsSulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg), placebo tablets
NCT01878357 phase4completednot on this mapstarted 2013, after this paper: background citation

Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial

TypeinterventionalSponsorIndonesia UniversityRan2013 to 2013Enrolled1,488ConditionsMalariaArmsdihydroartemisinin-piperaquine, primaquine
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 9 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Mass drug administration for malaria.The Cochrane database of systematic reviews · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Mass drug administration for malaria.The Cochrane database of systematic reviews · 2013
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. A systematic review and meta-analysis on sub-microscopicThe Lancet regional health. Southeast Asia · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 4 countries.

Seif A ShekalagheKilimanjaro Christian Medical College-Kilimanjaro Clinical Research Institute, Moshi, Tanzania. sshekalaghe@yahoo.com
Chris Drakeley
Sven van den Bosch
Roel ter Braak
Wouter van den Bijllaardt
Charles Mwanziva
Salimu Semvua
Alutu Masokoto
Frank Mosha
Karina Teelen
Rob Hermsen
Lucy Okell
Roly Gosling
Robert Sauerwein
Teun Bousema
Radboud University Nijmegen · NLKilimanjaro Christian Medical Centre · TZRadboud University Medical Center · NLChristian Medical College & Hospital · INImperial College London · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of London · GB

Funding

Wellcome Trust 063516
6 · The paper itself

Abstract

backgroundEffective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the intensity and seasonality of malaria transmission, the efficacy of the intervention in rapidly clearing all malaria parasite stages and the degree to which symptomatic and asymptomatic parasite carriers participate in the intervention. The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0.75 mg/kg) on malaria transmission was determined in an area of very low and seasonal malaria transmission in northern Tanzania.

methodsIn a cluster-randomized trial in four villages in Lower Moshi, Tanzania, eight clusters (1,110 individuals; cluster size 47- 209) were randomized to observed treatment with SP+AS+PQ and eight clusters (2,347 individuals, cluster size 55- 737) to treatment with placebo over three days. Intervention and control clusters were 1 km apart; households that were located between clusters were treated as buffer zones where all individuals received SP+AS+PQ but were not selected for the evaluation. Passive case detection was done for the entire cohort and active case detection in 149 children aged 1-10 year from the intervention arm and 143 from the control arm. Four cross-sectional surveys assessed parasite carriage by microscopy and molecular methods during a five-month follow-up period.

resultsThe coverage rate in the intervention arm was 93.0% (1,117/1,201). Parasite prevalence by molecular detection methods was 2.2-2.7% prior to the intervention and undetectable during follow-up in both the control and intervention clusters. None of the slides collected during cross-sectional surveys had microscopically detectable parasite densities. Three clinical malaria episodes occurred in the intervention (n = 1) and control clusters (n = 2).

conclusionsThis study illustrates the possibility to achieve high coverage with a three-day intervention but also the difficulty in defining suitable outcome measures to evaluate interventions in areas of very low malaria transmission intensity. The decline in transmission intensity prior to the intervention made it impossible to assess the impact of MDA in the chosen study setting.

trial registrationClinicalTrials.gov: NCT00509015.

Indexed as

AdolescentAdultAgedAged, 80 and overAntimalarialsArtemisininsArtesunateChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationEndemic DiseasesFemaleHumansInfantMalariaAntimalarialsArtemisininsArtesunateDrug Combinationsfanasil, pyrimethamine drug combinationPlacebosPrimaquinePyrimethamineSulfadoxine

Identifiers

PMID21864343
PMCPMC3169516
OpenAlexW2125987157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.